In an update Tuesday, Pfizer said it is discontinuing 15 of the projects in its development pipeline. The news comes a month after the world’s largest pharmaceutical company announced large research and development cuts were on…
The pharmaceutical industry is ready to fall off a cliff — a “patent cliff.” Over the next few years, some of the world’s most popular and lucrative medicines will go off patent, and generic competition will siphon an estimate…
Pfizer reported fourth-quarter earnings on Tuesday that nearly quadrupled from a year ago as revenue rose 6%. But it also lowered its sales guidance for 2012, due to some of its bestselling drugs going off patent. What’s ahead …
Lpath focuses on developing therapeutics that target bioactive lipids for treating a range of human diseases, including cancer and diseases that cause blindness. Its promising drugs have attracted attention — and lots of money…
Aside from the embarrassment, researchers know deceptions like the autism research fraud can have much larger consequences, both for the parents of autistic children and for the future of their studies. Says one prominent scien…